The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Adalimumab (Brand name: Humira)
- Manufactured by
FDA-approved indication: September 2018, adalimumab (Humira) received expanded approval for the treatment of non-infectious intermediate, posterior, and panuveitis to include pediatric patients 2 years of age and older. It was approved for use in adults with non-infectious intermediate, posterior, and panuveitis in June 2016.
National Library of Medicine Drug Information PortalMedline Plus Health Information